Purple Historical Income Statement

PPBT Stock

USD 2.69 0.05 1.82%

Historical analysis of Purple Biotech income statement accounts such as Research Development of 7.6 M, Total Operating Expenses of 8.3 M, Total Other Income Expense Net of 3.9 M or Interest Income of 337.9 K can show how well Purple Biotech performed in making a profits. Evaluating Purple Biotech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Purple Biotech's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Purple Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Purple Biotech is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Purple Stock please use our How to Invest in Purple Biotech guide.

About Purple Income Statement Analysis

Purple Biotech Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Purple Biotech shareholders. The income statement also shows Purple investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Purple Biotech Income Statement Chart

At this time, Purple Biotech's Depreciation And Amortization is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 4.5 M in 2025, whereas EBIT is likely to drop (7.6 M) in 2025.

Selling General Administrative Other Operating Expenses Research Development Cost Of Revenue

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Purple Biotech. It is also known as Purple Biotech overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Purple Biotech income statement and represents the costs associated with goods and services Purple Biotech provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from Purple Biotech's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Purple Biotech current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Purple Stock please use our How to Invest in Purple Biotech guide.At this time, Purple Biotech's Depreciation And Amortization is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 4.5 M in 2025, whereas EBIT is likely to drop (7.6 M) in 2025.

Purple Biotech income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Interest Income	Interest Income	Net Income From Continuing Ops	Minority Interest	Total Revenue	Gross Profit	Reconciled Depreciation	Discontinued Operations	Cost Of Revenue	Selling And Marketing Expenses
Depreciation And Amortization		0.02	0.1	0.36	0.0	-0.42	0.43	-0.4	0.19	-0.46	-0.12	-0.34	-0.32	-0.06	0.27	-0.45	-0.36	-0.45	-0.57	0.32	0.38	0.54	0.46
Interest Expense	0.02		0.24	0.51	0.62	-0.42	0.59	-0.42	-0.71	-0.33	-0.86	0.3	0.01	-0.88	0.27	-0.23	-0.39	-0.17	-0.36	0.29	-0.13	0.32	0.33
Selling General Administrative	0.1	0.24		0.82	-0.14	-0.78	0.66	-0.79	0.4	-0.74	-0.19	-0.64	-0.3	-0.03	0.44	-0.34	-0.68	-0.4	-0.4	0.7	-0.01	0.28	0.29
Other Operating Expenses	0.36	0.51	0.82		-0.03	-0.87	0.97	-0.87	0.17	-0.84	-0.44	-0.6	-0.14	-0.24	0.76	-0.52	-0.81	-0.74	-0.76	0.79	0.11	0.43	0.65
Operating Income	0.0	0.62	-0.14	-0.03		-0.23	0.01	-0.23	-0.78	-0.18	-0.84	0.61	-0.45	-0.68	-0.21	-0.35	0.07	0.43	0.15	0.03	-0.21	0.42	-0.15
Ebit	-0.42	-0.42	-0.78	-0.87	-0.23		-0.82	1.0	-0.19	0.98	0.55	0.58	0.54	0.14	-0.61	0.79	0.65	0.47	0.51	-0.76	0.1	-0.47	-0.37
Research Development	0.43	0.59	0.66	0.97	0.01	-0.82		-0.82	0.07	-0.78	-0.49	-0.52	-0.07	-0.3	0.82	-0.52	-0.8	-0.8	-0.83	0.76	0.13	0.43	0.72
Ebitda	-0.4	-0.42	-0.79	-0.87	-0.23	1.0	-0.82		-0.19	0.98	0.55	0.58	0.54	0.14	-0.61	0.79	0.65	0.46	0.51	-0.76	0.1	-0.46	-0.36
Total Operating Expenses	0.19	-0.71	0.4	0.17	-0.78	-0.19	0.07	-0.19		-0.24	0.7	-0.82	-0.15	0.82	0.23	-0.06	-0.21	-0.32	-0.08	0.24	0.14	-0.16	0.04
Income Before Tax	-0.46	-0.33	-0.74	-0.84	-0.18	0.98	-0.78	0.98	-0.24		0.52	0.65	0.49	0.05	-0.61	0.84	0.57	0.46	0.49	-0.71	0.12	-0.42	-0.33
Total Other Income Expense Net	-0.12	-0.86	-0.19	-0.44	-0.84	0.55	-0.49	0.55	0.7	0.52		-0.25	0.24	0.74	-0.22	0.56	0.2	0.01	0.23	-0.3	0.24	-0.41	-0.17
Net Income	-0.34	0.3	-0.64	-0.6	0.61	0.58	-0.52	0.58	-0.82	0.65	-0.25		0.07	-0.57	-0.57	0.44	0.4	0.6	0.4	-0.47	0.02	0.06	-0.25
Income Tax Expense	-0.32	0.01	-0.3	-0.14	-0.45	0.54	-0.07	0.54	-0.15	0.49	0.24	0.07		-0.03	0.02	0.54	0.24	-0.21	-0.09	-0.36	0.06	-0.49	0.14
Net Interest Income	-0.06	-0.88	-0.03	-0.24	-0.68	0.14	-0.3	0.14	0.82	0.05	0.74	-0.57	-0.03		0.11	-0.07	0.26	-0.07	0.24	-0.13	-0.12	-0.45	-0.28
Interest Income	0.27	0.27	0.44	0.76	-0.21	-0.61	0.82	-0.61	0.23	-0.61	-0.22	-0.57	0.02	0.11		-0.52	-0.62	-0.87	-0.73	0.62	0.07	0.22	0.65
Net Income From Continuing Ops	-0.45	-0.23	-0.34	-0.52	-0.35	0.79	-0.52	0.79	-0.06	0.84	0.56	0.44	0.54	-0.07	-0.52		0.2	0.29	0.28	-0.45	0.36	-0.24	-0.08
Minority Interest	-0.36	-0.39	-0.68	-0.81	0.07	0.65	-0.8	0.65	-0.21	0.57	0.2	0.4	0.24	0.26	-0.62	0.2		0.72	0.81	-0.91	-0.46	-0.63	-0.77
Total Revenue	-0.45	-0.17	-0.4	-0.74	0.43	0.47	-0.8	0.46	-0.32	0.46	0.01	0.6	-0.21	-0.07	-0.87	0.29	0.72		0.92	-0.66	-0.36	-0.27	-0.83
Gross Profit	-0.57	-0.36	-0.4	-0.76	0.15	0.51	-0.83	0.51	-0.08	0.49	0.23	0.4	-0.09	0.24	-0.73	0.28	0.81	0.92		-0.76	-0.53	-0.57	-0.93
Reconciled Depreciation	0.32	0.29	0.7	0.79	0.03	-0.76	0.76	-0.76	0.24	-0.71	-0.3	-0.47	-0.36	-0.13	0.62	-0.45	-0.91	-0.66	-0.76		0.33	0.63	0.67
Discontinued Operations	0.38	-0.13	-0.01	0.11	-0.21	0.1	0.13	0.1	0.14	0.12	0.24	0.02	0.06	-0.12	0.07	0.36	-0.46	-0.36	-0.53	0.33		0.65	0.72
Cost Of Revenue	0.54	0.32	0.28	0.43	0.42	-0.47	0.43	-0.46	-0.16	-0.42	-0.41	0.06	-0.49	-0.45	0.22	-0.24	-0.63	-0.27	-0.57	0.63	0.65		0.61
Selling And Marketing Expenses	0.46	0.33	0.29	0.65	-0.15	-0.37	0.72	-0.36	0.04	-0.33	-0.17	-0.25	0.14	-0.28	0.65	-0.08	-0.77	-0.83	-0.93	0.67	0.72	0.61

Click cells to compare fundamentals

Purple Biotech Account Relationship Matchups

Purple Biotech income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	235K	231K	49K	46K	186K	195.3K
Interest Expense	61K	212K	126K	2.2M	41K	39.0K
Selling General Administrative	6.1M	5.8M	6.0M	4.8M	2.9M	4.5M
Other Operating Expenses	13.8M	17.9M	22.6M	22.3M	11.0M	12.4M
Operating Income	12.6M	(17.9M)	(22.6M)	22.3M	(11.0M)	(11.6M)
Ebit	(28.6M)	(17.6M)	(21.5M)	(22.3M)	(7.2M)	(7.6M)
Research Development	7.5M	11.8M	16.3M	17.0M	7.6M	7.6M
Ebitda	(28.4M)	(17.4M)	(21.4M)	(22.2M)	(7.1M)	(7.4M)
Total Operating Expenses	13.8M	17.9M	22.6M	(22.5M)	11.0M	8.3M
Income Before Tax	(28.1M)	(17.8M)	(21.8M)	(20.0M)	(7.3M)	(7.6M)
Total Other Income Expense Net	(15.5M)	108K	843K	(42.2M)	3.7M	3.9M
Net Income	(12.4M)	(18.4M)	(21.7M)	(19.9K)	(7.2M)	(7.6M)
Income Tax Expense	(15.7M)	637K	877K	(97K)	(87.3K)	(91.7K)
Net Interest Income	193K	108K	843K	(1.7M)	(212K)	(201.4K)
Interest Income	254K	320K	969K	474K	260K	337.9K
Net Income From Continuing Ops	(28.1M)	(17.8M)	(21.8M)	(20.0M)	(7.3M)	(7.6M)
Net Income Applicable To Common Shares	(5.9M)	(28.0M)	(18.4M)	(21.7M)	(19.5M)	(20.5M)
Minority Interest	363K	84K	92K	97K	39K	37.1K
Gross Profit	765K	(55.0)	(120.0)	(196.0)	(176.4)	(167.58)
Reconciled Depreciation	235K	231K	201K	197K	186K	170.4K
Cost Of Revenue	235K	55.0	120.0	196K	225.4K	236.7K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Purple Stock Analysis

When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Purple Historical Income Statement

About Purple Income Statement Analysis

Purple Biotech Income Statement Chart

Other Operating Expenses

Cost Of Revenue

Purple Biotech income statement Correlations

Purple Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Purple Biotech income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Purple Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Income Before Tax	+ 0.98	Ebit
Income Before Tax	+ 0.98	Ebitda
Research Development	+ 0.97	Other Operating Expenses
Gross Profit	+ 0.92	Total Revenue
Net Income From Continuing Ops	+ 0.84	Income Before Tax

Selling And Marketing Expenses	- 0.93	Gross Profit
Reconciled Depreciation	- 0.91	Minority Interest
Net Interest Income	- 0.88	Interest Expense
Total Revenue	- 0.87	Interest Income
Ebitda	- 0.87	Other Operating Expenses
Ebit	- 0.87	Other Operating Expenses